Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -172.61M | -166.01M | -165.67M | -132.00M | -99.79M |
| Total Depreciation and Amortization | 301.00K | 326.00K | 350.00K | 340.00K | 326.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.32M | 5.82M | 5.03M | 4.88M | 3.68M |
| Change in Net Operating Assets | 10.06M | 28.58M | 47.10M | 30.30M | 3.50M |
| Cash from Operations | -155.92M | -131.28M | -113.20M | -96.49M | -92.28M |
| Capital Expenditure | -153.00K | -42.00K | -91.00K | -270.00K | -309.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 55.26M | 114.90M | 100.40M | 85.78M | 80.07M |
| Cash from Investing | 55.11M | 114.86M | 100.31M | 85.51M | 79.76M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 173.40M | 173.40M | 65.29M | 65.32M | 66.00K |
| Repurchase of Common Stock | -636.00K | -201.00K | -201.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 172.77M | 173.20M | 65.09M | 65.32M | 66.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.95M | 156.79M | 52.19M | 54.34M | -12.46M |